Because selective TRPV2 antagonists are not commercially available, further mechanistic studies including TRPV2 knockout mouse might be needed to determine the exact involvement of TRPV2 in cisplatin-induced neuropathy. The gene discussed is TRPV2; the disease is neuropathy.